Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

Inclusion Criteria: * ECOG performance status (PS) 0, 1, or 2 * Diagnosis of symptomatic multiple myeloma * High risk myeloma as defined by progressive disease =\< 12 months after high dose chemotherapy and autologous HSC transplant or presences of poor prognostic features such as deletion of chromosome 13 or hypodiploidy by standard cytogenetics, or t(4; 14) by fluorescence in situ hybridization (FISH), or t(14;16) by FISH, or 17p- by FISH, or plasma cell labeling index \>= 3% * Availability of a HLA fully-matched or 1 mismatch related donor by low-resolution HLA typing for the loci A, B, C, DRB1 and DQB1 or HLA fully-matched unrelated donor by high-resolution typing for loci A, B, C and DRB1 and at least low-resolution for loci DQB1 * Recovery from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and hematological toxicity) * Physically and psychologically capable of undergoing bone marrow or PBSC transplant * Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control for the during of the study * Male subject agrees to use an acceptable method for contraception for the duration of the study Exclusion Criteria: * Myocardial infarction within 6 months prior…